

## Clinical Policy: Orlistat (Xenical)

Reference Number: HNCA.CP.CPA.335

Effective Date: 06.01.18

Last Review Date: 11.25

Line of Business: Commercial, HIM

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Orlistat (Xenical®) is a reversible inhibitor of gastrointestinal lipases.

### FDA Approved Indication(s)

Xenical is indicated:

- For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet
- To reduce the risk for weight regain after prior weight loss

### Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria:

- Body Mass Index requirements (*see Appendix B*)
- Participation in an approved weight loss program for at least 6 months prior to use of GLP-1 agonist, which includes:
  - A reduced calorie diet
  - Increased physical activity
  - Behavioral modification program
- Member must agree to continue the behavioral modification program throughout treatment with weight loss medication.

It is the policy of Health Net of California that orlistat or Xenical is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Weight Management (must meet all):

1. Member meets one of the following (a, b, or c):
  - a.  $BMI \geq 30 \text{ kg/m}^2$ ;
  - b.  $BMI \geq 27 \text{ kg/m}^2$  with at least one indicator of increased cardiovascular risk (e.g., coronary artery/heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference) or other obesity-related medical condition (e.g., sleep apnea);
  - c. If age is between 12 and 17 years:  $BMI \geq 95^{\text{th}}$  percentile standardized for age and sex (*see Appendix D*);
2. Age  $\geq 12$  years;
3. Documentation supports member's participation in a Health Net approved weight loss program (e.g., Weight Watchers, Active&Fit) or other lifestyle modification plan

## CLINICAL POLICY

### Orlistat

recommended by the prescriber that involves a reduced calorie diet, increased physical activity, and behavioral modification that meets all of the following (a and b):

- a. Active participation in a weight loss program for at least 6 months prior to use of orlistat;
  - b. Will continue to be actively enrolled in a weight loss program or lifestyle modification plan recommended by the prescriber while concomitantly prescribed orlistat;
4. Documentation of member's current height and body weight to calculate BMI within the last 30 days;
  5. Follow-up visits are planned to assess adherence and response to the treatment plan;
  6. For brand Xenical requests, member must use generic orlistat, unless contraindicated or clinically significant adverse effects are experienced;
  7. Dose does not exceed 360 mg (3 capsules) per day.

**Approval duration: 12 weeks**

#### **B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

## **II. Continued Therapy**

#### **A. Weight Management (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
  - a. If this is the first renewal request, member has lost  $\geq 5\%$  of baseline body weight (adults) or baseline BMI (pediatrics);

## CLINICAL POLICY

### Orlistat

- b. If this is a second or subsequent renewal request, member has lost weight and/or maintained weight loss on therapy;
3. Documentation of member's current weight within the last 30 days;
4. Follow-up visits are planned to assess adherence and response to the treatment plan;
5. Documentation that member is actively enrolled in a Health Net approved weight loss program (e.g., Weight Watchers, Active&Fit) or other lifestyle modification plan recommended by the prescriber that involves a reduced calorie diet, increased physical activity, and behavioral modification adjunct to therapy;
6. For brand Xenical requests, member must use generic orlistat, unless contraindicated or clinically significant adverse effects are experienced;
7. If request is for a dose increase, new dose does not exceed 360 mg (3 capsules) per day.

**Approval duration:**

**First reauthorization** – 12 weeks

**Second or subsequent reauthorizations** – 6 months

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

BMI: body mass index

FDA: Food and Drug Administration

## CLINICAL POLICY

### Orlistat

#### Appendix B: WHO Classification of Weight Status

Weight Status	Body Mass Index (BMT), kg/m <sup>2</sup>
Underweight	<18.5
Normal range	18.5 - 24.9
Overweight	25.0 - 29.9
Obese	≥30
Class I	30.0 – 34.9
Class II	35.0 – 39.9
Class III	≥40

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): pregnancy, chronic malabsorption syndrome, cholestasis, known hypersensitivity to Xenical or any component of this product
- Boxed warning(s): none reported

#### Appendix D: General Information

- $BMI = 703 \times [\text{weight (lbs)/height (inches)}^2]$
- Examples of coronary artery/heart disease include: coronary artery bypass graft, angina, history of myocardial infarction or stroke.
- An effective response to a weight loss medication is defined by the Endocrine Society (2015) as weight loss  $\geq 5\%$  of body weight at 3 months of therapy. If there is weight loss  $< 5\%$  of body weight, the Endocrine Society recommends discontinuation of the medication.
- BMI cut-offs (95<sup>th</sup> percentile) for obesity by age and sex for pediatric patients aged  $\geq 12$  years:

Age (in years)	95 <sup>th</sup> Percentile BMI Value	
	Male	Female
12	24.2	25.2
12.5	24.7	25.7
13	25.1	26.3
13.5	25.6	26.8
14	26.0	27.2
14.5	26.4	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.5	28.9
16.5	27.9	29.3
17	28.2	29.6
17.5	28.6	30.0

## CLINICAL POLICY

### Orlistat

#### V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Weight management	120 mg PO TID with each main meal containing fat	360 mg/day

#### VI. Product Availability

Capsule: 120 mg

#### VII. References

1. Xenical Prescribing Information. Montgomery, AL: H2-Pharma, LLC. Available at: <https://www.xenical.com>.
2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014; 129(suppl 2): S102–S138.
3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015; 100(2): 42-362.
4. Grunvald E, Shah R, Hernaez R et al. AGA clinical practice guidelines on pharmacological interventions for adults with obesity. *Gastroenterology* 2022;163:1198-1225.
5. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity [published online ahead of print, 2023 Jan 9]. *Pediatrics*. 2023;e2022060640.
6. Data Table of BMI-for-Age Charts. CDC National Center for Health Statistics. Available at: <https://www.cdc.gov/growthcharts/cdc-charts.htm>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2021 annual review: no significant changes; references reviewed and updated.	02.02.21	05.21
2Q 2022 annual review: no significant changes; WCG.CP.CPA.335 for off-label use of orlistat retired per health plan; references reviewed and updated.	01.24.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.28.22	
2Q 2023 annual review: FDA indications updated per PI; added redirection to generic orlistat for brand Xenical requests per formulary status; for age between 12 and 17 years added obesity defined as BMI $\geq$ 95 <sup>th</sup> percentile standardized for age and sex; removed continued therapy criterion of BMI $\geq$ 25 kg/m <sup>2</sup> ; specified continuation of therapy positive response criterion of $\geq$ 5% loss of baseline body weight for adults and BMI for pediatrics; references reviewed and updated.	01.11.23	05.23

**CLINICAL POLICY**  
Orlistat

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2024 annual review: for documentation of weight loss program, added members has been actively enrolled for at least 6 months to initial criteria and added a weight loss program that also involves behavioral modification as supported by ACC/AHA guidelines; references reviewed and updated.	01.16.24	05.24
2Q 2025 annual review: no significant changes; references reviewed and updated.	01.15.25	05.25
New CA policy. <ul style="list-style-type: none"> <li>- Added HIM LOB;</li> <li>- Added documentation of current height and weight within the last 30 days to initial criteria. For reauth, only current weight within the last 30 days is required;</li> <li>- Added documentation that member will have f/u visit to assess adherence and response to therapy;</li> <li>- Added examples of HN approved weight loss programs;</li> <li>- Added WHO Classification of Weight Status in Appendix B;</li> <li>- Lifestyle modification plan added;</li> <li>- References updated.</li> </ul>	11.14.25	11.25

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

## CLINICAL POLICY

### Orlistat

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.